FineMark National Bank & Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

FineMark National Bank & Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-180	Closed	-$22K	–	1322
2016 Q3	$22K	Sell	180 -54	-23%	-$7.28K	﹤0.01%	795
2016 Q2	$33K	Buy	234 +54	+30%	+$7.96K	﹤0.01%	712
2016 Q1	$23K	Hold	180	–	–	﹤0.01%	758
2015 Q4	$25K	Hold	180	–	–	﹤0.01%	777
2015 Q3	$24K	Sell	180 -13	-7%	-$2.24K	﹤0.01%	810
2015 Q2	$34K	Hold	193	–	–	﹤0.01%	756
2015 Q1	$34K	Sell	193 -35	-15%	-$6.01K	﹤0.01%	762
2014 Q4	$37K	Hold	228	–	–	0.01%	749
2014 Q3	$37K	Hold	228	–	–	0.01%	718
2014 Q2	$33K	Hold	228	–	–	0.01%	748
2014 Q1	$32K	Sell	228 -105	-32%	-$15.8K	0.01%	734
2013 Q4	$42K	Hold	333	–	–	0.01%	614
2013 Q3	$31K	Buy	333 +263	+376%	+$21.2K	0.01%	676
2013 Q2	$5K	Buy	+70	New	+$4.28K	﹤0.01%	1097

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FineMark National Bank & Trust's JAZZ Position: Q4 2016 in Review

FineMark National Bank & Trust sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2016, closing a stake of 180 shares — an estimated $22K sold.

FineMark National Bank & Trust first reported a position in JAZZ in Q2 2013 and held it in 14 quarters. The position peaked at $42K in Q4 2013. 295 funds tracked by Wall St. Rank hold JAZZ as of Q4 2016.

FineMark National Bank & Trust reported no remaining Jazz Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
FineMark National Bank & Trust sold 180 Jazz Pharmaceuticals shares in Q4 2016, an estimated $22K.
FineMark National Bank & Trust first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 14 quarters.
FineMark National Bank & Trust's Jazz Pharmaceuticals position peaked at $42K in Q4 2013.
295 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2016.

Based on FineMark National Bank & Trust's 13F filing for Q4 2016, filed 13 Feb 2017.